Literature DB >> 19936072

The 2007 ERA-EDTA Registry Annual Report-a Précis.

Vianda S Stel1, Anneke Kramer, Carmine Zoccali, Kitty J Jager.   

Abstract

Entities:  

Year:  2009        PMID: 19936072      PMCID: PMC2779783          DOI: 10.1093/ndtplus/sfp126

Source DB:  PubMed          Journal:  NDT Plus        ISSN: 1753-0784


× No keyword cloud information.

Introduction

This summary of the 2007 ERA-EDTA Registry Report includes data on renal replacement therapy (RRT) from 49 national and regional registries in 28 countries in Europe and bordering the Mediterranean Sea (Figure 1). Data sets with individual patient data for analysis were received from 34 registries, whereas 17 registries contributed data only in aggregated form. For both types of registries, we present incidence and prevalence data as well as transplant rates. Survival analysis used the data from countries and regions that provided individual patient records. More detailed data than those presented in this paper can be found in the 2007 ERA-EDTA Registry Report [1] that is also available on www.era-edta-reg.org.
Fig. 1

Incidence of RRT per million population (pmp) at Day 1, 2007. B&H = Bosnia–Herzegovina; FYROM = Former Yugoslav Republic of Macedonia.

Incidence of RRT per million population (pmp) at Day 1, 2007. B&H = Bosnia–Herzegovina; FYROM = Former Yugoslav Republic of Macedonia.

The incidence of RRT for ESRD across Europe

In 2007, the overall incidence rate of RRT for end-stage renal disease (ESRD) among all registries reporting to the ERA-EDTA Registry was 116 per million population (pmp). Figure 2 shows that the highest incidence rates at Day 1 were reported by Turkey (231 pmp), Portugal (227 pmp) and Israel (193 pmp), whereas incidence rates below 100 pmp were reported by Ukraine (20 pmp), Russia (31 pmp), Montenegro (32 pmp), Iceland (81 pmp), Latvia (86 pmp), Romania (90 pmp), Finland (92 pmp) and FYR of Macedonia (92 pmp). The mean age at the start of RRT ranged from 43 years (Ukraine) to 69 years (Belgium) (Figure 2). Table 1 shows the incidence rate of RRT over the period 2003–2007 for countries and regions providing individual patient data, adjusted for age and gender distribution.
Fig. 2

Incidence of RRT per million population (pmp) and mean age (years) at Day 1 in 2007, unadjusted. Figures include data from renal registries providing individual patient data (left figure) and aggregated data (right figure). Data of Estonia and Tunisia are based on Day 91 of RRT.

Table 1

Incidence of RRT over the period 2003–2007 per million population (pmp) at Day 1, adjusted for age and gender distribution

Country /regions
providing individual20032004200520062007
patient datapmppmppmppmppmp
Austria138156148153146
Belgium, Dutch-speaking160163163169161
Belgium, French-speaking156179171180178
Denmark133131119117136
Finland9394928385
Greece168177171172164
Iceland8387817984
Italy, Calabria130137127121132
Norway97102101101113
Spain, Andalusia137138141139125
Spain, Aragon8711411993113
Spain, Asturias108132101102103
Spain, Basque country1281121079998
Spain, Cantabria12613514211599
Spain, Castile and Leon981009110199
Spain, Castile-La Mancha105113125109102
Spain, Catalonia144132141125130
Spain, Valencian region148157140144137
Sweden113113110117117
The Netherlands108110109114117
United Kingdom, England7386107111107
United Kingdom, Scotland117110119109106
United Kingdom, Wales121112122126129
All countries111118123124122
Incidence of RRT per million population (pmp) and mean age (years) at Day 1 in 2007, unadjusted. Figures include data from renal registries providing individual patient data (left figure) and aggregated data (right figure). Data of Estonia and Tunisia are based on Day 91 of RRT. Incidence of RRT over the period 2003–2007 per million population (pmp) at Day 1, adjusted for age and gender distribution For the age group 0–19 years at the start of RRT, data were available for a limited number of registries including those of Austria, Denmark, Finland, Greece, Iceland, Norway, Romania, Spain (Andalusia), Spain (Aragon), Spain (Basque country), Spain (Catalonia), Spain (Valencian region), Sweden, The Netherlands, and United Kingdom (Scotland). As numbers of children starting RRT were low, we present averages for 2006–2007 (Table 2). In 2007, the ERA-EDTA Registry started a close collaboration with the ESPN/ERA-EDTA Registry that initiated data collection from paediatric registries across Europe [2]. For an overview of paediatric RRT data collected from those registries, please visit www.espn-reg.org.
Table 2

Incidence of RRT over the period 2006–2007 per million age-related population (pmarp) per year at Day 1, by age group, unadjusted

0–190–45–910–1415–19
Cohortpmarppmarppmarppmarppmarp
2006–20071085816
Incidence of RRT over the period 2006–2007 per million age-related population (pmarp) per year at Day 1, by age group, unadjusted Table 3 shows the incidence rate of RRT by age group, for countries and regions providing individual patient data. For the highest age groups, the highest incidence rates were reported from Belgium and Greece, whereas Finland and Romania belong to the countries reporting the lowest incidence rates.
Table 3

Incidence of RRT per million age related population (pmarp) at Day 1 in 2007, by age group, unadjusted

Country/regions
providing individual0–1920–4445–6465–7475+
patient datapmarppmarppmarppmarppmarp
Austria1041191488551
Belgium, Dutch-speaking39171542899
Belgium, French-speaking34209649848
Denmark1051179435524
Finland1140132231238
Greece943188536839
Iceland1145137163340
Italy (12 of 20 regions)742143406561
Norway642151381416
Romania847161251136
Spain, Andalusia946160442437
Spain, Aragon947136490304
Spain, Asturias44141323378
Spain, Basque country338132340326
Spain, Cantabria41145362263
Spain, Castile and Leon34128378358
Spain, Castile-La Mancha31145360369
Spain, Catalonia744176402523
Spain, Valencian region851187392582
Sweden944156396428
The Netherlands1042147393448
United Kingdom, All countries55154331334
United Kingdom, England55153325321
United Kingdom, Northern Ireland42141463493
United Kingdom, Scotland1559158278317
United Kingdom, Wales54163435491
Incidence of RRT per million age related population (pmarp) at Day 1 in 2007, by age group, unadjusted The incidence rates of RRT for ESRD due to diabetes mellitus were highest in Israel (81 pmp), Turkey (64 pmp), and Slovakia (60 pmp), whereas the highest incidence rates of RRT for ESRD due to hypertension/renal vascular disease were reported from Turkey (58 pmp), and Belgium (52 pmp) (Table 4).
Table 4

Incidence of RRT per million population (pmp) at Day 1 in 2007, by primary renal disease, unadjusted

Country/regionsHT/Unkn/
providing individualAllDMRVDGNOthermissing
patient datapmppmppmppmppmppmp
Austria1524834163717
Belgium, Dutch-speaking1864452195616
Belgium, French-speaking185425219648
Denmark1413218155027
Finland92326112418
Greece1905322163762
Iceland8110356263
Italy (12 of 20 regions)1503036163534
Norway113153519404
Romania90116153028
Spain, Andalusia1212720163325
Spain, Aragon1303124244111
Spain, Asturias1332821103341
Spain, Basque country1131725124217
Spain, Cantabria111193640124
Spain, Castile and Leon1273222143326
Spain, Castile-La Mancha1093314123020
Spain, Catalonia1372823193234
Spain, Valencian region1452537183332
Sweden1293525163814
The Netherlands1182126112832
United Kingdom, All countries1112312133132
United Kingdom, England1092211123033
United Kingdom, Northern Ireland1142616124417
United Kingdom, Scotland1142013134127
United Kingdom, Wales1423615253234
Bosnia-Herzegovina1643316147031
Czech Republic
Estonia
France (18 of 24 regions)1393136163719
FYR of Macedonia92212472119
Israel193811992857
Italy (14 of 20 regions)1452936153332
Latvia861511114010
Montenegro3218635
Poland1283217233817
Portugal
Russia315211112
Slovakia160601613637
Spain (17 of 19 regions)1263022163226
Tunisia
Turkey2316458244145
Ukraine20311061

DM: diabetes mellitus; HT: hypertension; RVD: renal vascular disease; GN: glomerulonephritis/sclerosis; others include pyelonephritis, polycystic kidneys, adult type and miscellaneous; Unkn: unknown.

Categories may not add up because of rounding off.

When cells are left empty, (complete) data are unavailable.

Incidence of RRT per million population (pmp) at Day 1 in 2007, by primary renal disease, unadjusted DM: diabetes mellitus; HT: hypertension; RVD: renal vascular disease; GN: glomerulonephritis/sclerosis; others include pyelonephritis, polycystic kidneys, adult type and miscellaneous; Unkn: unknown. Categories may not add up because of rounding off. When cells are left empty, (complete) data are unavailable.

The prevalence of RRT for ESRD across Europe

The overall prevalence among all registries reporting to the ERA-EDTA Registry was 662 pmp. Figure 3 shows that the prevalence of RRT pmp at 31 December 2007 was highest in Portugal (1372 pmp), Belgium (French-speaking) (1109 pmp) and Spain (Catalonia) (1100 pmp). The lowest prevalence was reported by Ukraine (85 pmp) and Russia (146 pmp). The mean age at 31 December 2007 ranged from 44 years (Russia and Ukraine) to 64 years (Belgium, Dutch speaking) for registries providing data both on dialysis and transplant patients (Figure 3). Table 5 shows the overall prevalence of RRT, adjusted for age and gender distribution.
Fig. 3

Prevalence of RRT per million population (pmp) and mean age (years) on 31 December 2007, unadjusted. Figures include data from renal registries providing individual patient data (left figure) and aggregated data (right figure). Data from Czech Republic, Israel, Italy (14 of 20 regions), Slovakia and Tunisia include dialysis patients only, and in Italy (12 of 20 regions) the percentage of missing prevalent RRT patients is estimated at 11%, due to an estimated 25–30% underreporting of patients living on a functioning graft.

Table 5

Prevalence of RRT on 31 December over the period 2003–2007 per million population (pmp), adjusted for age and gender distribution

Country/region
regions providing20032004200520062007
individual patient datapmppmppmppmppmp
Austria794829854875894
Belgium, Dutch-speaking848876908939962
Belgium, French-speaking929978101010541087
Denmark730751760768798
Finland642659680686699
Greece848851872885900
Iceland535532527526551
Italy, Calabria897906909913928
Norway687725743763791
Spain, Andalusia939968999996981
Spain, Aragon699727755769792
Spain, Asturias765814827835837
Spain, Basque country872902937948965
Spain, Cantabria722746747745736
Spain, Castile and Leon742764776784779
Spain, Castile-La Mancha865867897900901
Spain, Catalonia10071037102810281060
Spain, Valencian region10221058104410471050
Sweden753772783804816
The Netherlands691711736768791
United Kingdom, England441538690712742
United Kingdom, Scotland707717741759782
United Kingdom, Wales658663685710780
All countries686733798815834
Prevalence of RRT per million population (pmp) and mean age (years) on 31 December 2007, unadjusted. Figures include data from renal registries providing individual patient data (left figure) and aggregated data (right figure). Data from Czech Republic, Israel, Italy (14 of 20 regions), Slovakia and Tunisia include dialysis patients only, and in Italy (12 of 20 regions) the percentage of missing prevalent RRT patients is estimated at 11%, due to an estimated 25–30% underreporting of patients living on a functioning graft. Prevalence of RRT on 31 December over the period 2003–2007 per million population (pmp), adjusted for age and gender distribution Only a limited number of registries provided complete data for prevalent patients in the age group 0–19 years in 2007, including those of Austria, Denmark, Finland, Greece, Iceland, Norway, Romania, Spain (Andalusia), Spain (Aragon), Spain (Basque country), Spain (Catalonia), Spain (Valencian region), Sweden, The Netherlands and United Kingdom (Scotland). The prevalence for age group 0–19 years is presented in Table 6.
Table 6

Prevalence of RRT per million age-related population (pmarp) on 31 December 2007, by age group, unadjusted

0–190–45–910–1415–19
Yearpmarppmarppmarppmarppmarp
200757193857108
Prevalence of RRT per million age-related population (pmarp) on 31 December 2007, by age group, unadjusted Table 7 shows that for the highest age groups, the highest prevalence was reported by Belgium, Greece, Italy, and several Spanish registries.
Table 7

Prevalence of RRT per million age related population (pmarp) on 31 December 2007, by age group, unadjusted

Country/regions
providing individual0–1920–4445–6465–7475+
patient datapmarppmarppmarppmarppmarp
Austria59461155824171829
Belgium, Dutch-speaking410145027093466
Belgium, French-speaking484169830723322
Denmark65562127319571662
Finland110432123715591220
Greece50428139525322764
Iceland6845481910351303
Italy (12 of 20 regions)41402135025663024
Norway61494130820541618
Romania21228728825396
Spain, Andalusia61509165326232213
Spain, Aragon30398139421191867
Spain, Asturias489140422431810
Spain, Basque country122501162925492032
Spain, Cantabria380134020311383
Spain, Castile and Leon445137320241732
Spain, Castile-La Mancha446161325421831
Spain, Catalonia57467177529672800
Spain, Valencian region58480170529132966
Sweden66488143920631610
The Netherlands68484125420951731
United Kingdom, All countries535123218091462
United Kingdom, England526122718121436
United Kingdom, Northern Ireland545129422752097
United Kingdom, Scotland76620125316831259
United Kingdom, Wales536125717541892
Prevalence of RRT per million age related population (pmarp) on 31 December 2007, by age group, unadjusted

Renal transplants

Figure 4 shows that the highest transplant rates were reported from Spain (Cantabria) (71 pmp), Spain (Catalonia) (65 pmp) and Norway (55 pmp). Countries with the highest transplant rates with living donor kidneys included Iceland (23 pmp), The Netherlands (23 pmp) and Norway (18 pmp).
Fig. 4

Renal transplants performed per million population (pmp) in 2007, by donor type, unadjusted. Figures include data from renal registries providing individual patient data (left figure) and aggregated data (right figure).

Renal transplants performed per million population (pmp) in 2007, by donor type, unadjusted. Figures include data from renal registries providing individual patient data (left figure) and aggregated data (right figure).

Patient and graft survival

Survival analysis used the data from 20 registries in 12 countries that provided individual patient records for the periods 1998–2002 and 2001–2005. Data are presented for all countries and regions together (Table 8 and Figures 5–7). Comparisons of survival by treatment modality were all adjusted for fixed values of age, gender and distribution of PRD. Similar adjustments have been applied to survival comparisons by PRD (please, consult appendix for fixed values and further methodology). Survival of incident dialysis patients and of patients receiving a first transplant between 1998–2002, by treatment modality, adjusted for age, gender and primary renal disease. Survival of incident haemodialysis patients in 1998–2002, from Day 91, by primary renal disease, adjusted for age and gender. Survival of incident peritoneal dialysis patients in 1998–2002, from Day 91, by primary renal disease, adjusted for age and gender. One-, 1- and 5-year survival probabilities, unadjusteda aFor analysis methods, see the appendix.
Table 8

One-, 1- and 5-year survival probabilities, unadjusteda

Cohort 1998–2002Cohort 2001–2005
1 year2 years5 years1 years2 years
Patient survival on RRT80.9 (80.7–81.2)69.3 (69.0–69.5)46.1 (46.0–46.3)80.9 (80.6–81.1)69.5 (69.3–69.7)
Patient survival on dialysis80.3 (80.0–80.5)67.2 (67.0–67.5)38.3 (38.2–38.5)80.2 (79.9–80.4)67.6 (67.3–67.8)
Patient survival after first transplant (deceased donor)95.6 (95.3–96.0)93.7 (93.2–94.1)86.6 (86.1–87.2)95.6 (95.3–96.0)93.7 (93.3–94.0)
Patient survival after first transplant (living donor)97.7 (97.0–98.1)96.9 (96.2–97.5)94.0 (93.1–94.7)97.4 (96.8–97.9)96.6 (96.0–97.1)
Graft survival after first transplant (deceased donor)90.0 (89.5–90.5)87.0 (86.5–87.6)77.5 (76.9–78.1)90.0 (89.5–90.4)87.1 (86.5–87.5)
Graft survival after first transplant (living donor)94.4 (93.5–95.2)92.6 (91.7–93.5)86.0 (84.9–87.1)93.8 (93.0–94.5)92.0 (91.2–92.8)

aFor analysis methods, see the appendix.

  1 in total

1.  Progress with the European Society for Paediatric Nephrology (ESPN)/ERA-EDTA Registry for children with established renal failure (ERF).

Authors:  E Jane Tizard; Enrico Verrina; Karlijn J van Stralen; Kitty J Jager
Journal:  Nephrol Dial Transplant       Date:  2009-06-27       Impact factor: 5.992

  1 in total
  8 in total

Review 1.  Statins, inflammation and kidney disease.

Authors:  Vera Krane; Christoph Wanner
Journal:  Nat Rev Nephrol       Date:  2011-05-31       Impact factor: 28.314

Review 2.  End-stage renal disease.

Authors:  Maaz Ahmed Abbasi; Glenn M Chertow; Yoshio N Hall
Journal:  BMJ Clin Evid       Date:  2010-07-19

3.  Demographics of paediatric renal replacement therapy in Europe: 2007 annual report of the ESPN/ERA-EDTA registry.

Authors:  Karlijn J van Stralen; E Jane Tizard; Enrico Verrina; Franz Schaefer; Kitty J Jager
Journal:  Pediatr Nephrol       Date:  2010-02-23       Impact factor: 3.714

4.  [Profile of chronic renal failure in diabetes at initiation of hemodialysis in the nephrology and dialysis service of the military hospital in Rabat, Morocco].

Authors:  Mohamed Reda El Farouki; Abdelaali Bahadi; Mohamed Amine Hamzi; Driss Kabbaj; Mohammed Benyahia
Journal:  Pan Afr Med J       Date:  2013-08-07

5.  [Profile of diabetic in chronic hemodialysis: a multicenter study in Morocco].

Authors:  Nadia Kabbali; Souad Mikou; Nada Tazi El Pardiya; Ghita El Bardai; Mohamed Arrayhani; Tarik Sqalli Houssaini
Journal:  Pan Afr Med J       Date:  2014-02-21

6.  Diet in chronic kidney disease in a Mediterranean African country.

Authors:  Khawla Kammoun; Hanen Chaker; Hichem Mahfoudh; Nouha Makhlouf; Faical Jarraya; Jamil Hachicha
Journal:  BMC Nephrol       Date:  2017-01-23       Impact factor: 2.388

7.  Causes of end stage renal failure among haemodialysis patients in Khartoum State/Sudan.

Authors:  Amin S I Banaga; Elaf B Mohammed; Rania M Siddig; Diana E Salama; Sara B Elbashir; Mohamed O Khojali; Rasha A Babiker; Khalifa Elmusharaf; Mamoun M Homeida
Journal:  BMC Res Notes       Date:  2015-09-29

8.  Renal biopsy in patients over 75: 131 cases.

Authors:  Cristiana Rollino; Michela Ferro; Giulietta Beltrame; Giacomo Quattrocchio; Carlo Massara; Francesco Quarello; Dario Roccatello
Journal:  Clin Nephrol       Date:  2014-10       Impact factor: 0.975

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.